`Sent: Thursday, February 15, 2018 11:36 AM
`To: Trials <Trials@USPTO.GOV>
`Cc: Tyler Liu <TLiu@agpharm.com>; Kallas,Nicholas <NKallas@fchs.com>; mphillips@lpiplaw.com;
`Zullow, Keith A <KZullow@goodwinlaw.com>; ZortessAfinitorIPR@fchs.com
`Subject: IPR2016-01479
`
`Dear Board:
`Petitioner West-Ward Pharmaceuticals International Ltd. (“West-Ward”) respectfully requests that
`the Board not issue a final written decision today (i.e., at the 1-year deadline measured from
`institution of lead IPR2016-01479, which has settled) and instead “adjust the time period[]” for a
`final written decision in the joined proceedings pursuant to 35 USC §316(a)(11) to give West-Ward
`time to investigate settlement with Patent Owner. West-Ward contacted Novartis and Argentum
`with respect to this request. Argentum has indicated that Argentum does not object to West-Ward’s
`request. West-Ward has not yet received a response from Novartis.
`Respectfully submitted,
`Counsel For West-Ward Pharmaceuticals International Ltd.
`Marta E. Delsignore
`Reg. No. 32,689
`Marta E. Delsignore
`
`Goodwin Procter LLP
`The New York Times Building
`620 Eighth Avenue
`New York, NY 10018
`o +1 212 813 8822
`f +1 646 558 4079
`MDelsignore@goodwinlaw.com | goodwinlaw.com
`
`*******************************************************************
`This message was sent from Goodwin Procter LLP and is intended only for the designated
`recipient(s). It may contain confidential or proprietary information and may be subject to the
`attorney-client privilege or other confidentiality protections. If you are not a designated
`recipient, you may not review, copy or distribute this message. If you receive this in error,
`please notify the sender by reply e-mail and delete this message. Thank you.
`*******************************************************************
`
`